Personalis, Inc.

NasdaqGM:PSNL Voorraadrapport

Marktkapitalisatie: US$238.8m

Personalis Beheer

Beheer criteriumcontroles 2/4

De CEO Personalis is Chris Hall, benoemd in Dec2022, heeft een ambtstermijn van 1.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.73M, bestaande uit 30.9% salaris en 69.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.31% van de aandelen van het bedrijf, ter waarde $ 616.21K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 2.5 jaar.

Belangrijke informatie

Chris Hall

Algemeen directeur

US$1.7m

Totale compensatie

Percentage CEO-salaris30.9%
Dienstverband CEO1.9yrs
Eigendom CEO0.3%
Management gemiddelde ambtstermijn3.3yrs
Gemiddelde ambtstermijn bestuur2.5yrs

Recente managementupdates

Recent updates

Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 19
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

The Proper Play On Personalis

Oct 28

Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Sep 14
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Jul 25
A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Apr 19
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Mar 02
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Dec 18
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Dec 04
Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Sep 04
Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

Apr 17
Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

The Prognosis For Personalis

Jun 16

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Jun 09
Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Feb 17
Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Personalis: Getting Personal Again

Feb 02

Analyse CEO-vergoeding

Hoe is Chris Hall's beloning veranderd ten opzichte van Personalis's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$91m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$2mUS$534k

-US$108m

Sep 30 2023n/an/a

-US$113m

Jun 30 2023n/an/a

-US$110m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$2mUS$83k

-US$113m

Compensatie versus markt: De totale vergoeding ($USD 1.73M ) Chris } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.47M ).

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Hall (55 yo)

1.9yrs

Tenure

US$1,726,790

Compensatie

Mr. Christopher M. Hall, also known as Chris, served as Senior Vice President and Head of Diagnostics Business at Personalis, Inc. since October 2022 until December 31, 2022 and serves as its President sin...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christopher Hall
President1.9yrsUS$1.73m0.31%
$ 750.1k
Aaron Tachibana
CFO & COO5.7yrsUS$1.67m0.27%
$ 650.4k
Stephen Moore
Senior VP & Chief Legal Officer4.6yrsUS$674.28k0.12%
$ 283.8k
Richard Chen
Executive VP of R&D and Chief Medical Officer3.3yrsUS$1.28m0.19%
$ 448.1k
Russ Altman
Co-Founder and Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Euan Ashley
Co-Founder and Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Michael Snyder
Co-Founder and Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Michael Fitzpatrick
Vice President of Worldwide Sales11.6yrsgeen gegevensgeen gegevens
Christian Haudenschild
Senior Vice President of Genomic Laboratory Operations3.2yrsgeen gegevensgeen gegevens
Stephane Mouradian
Senior Vice President of Business Development1.8yrsgeen gegevensgeen gegevens
Deepshikha Bhandari
Senior Vice President of Regulatory1.1yrsgeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PSNL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Christopher Hall
President1.7yrsUS$1.73m0.31%
$ 750.1k
Russ Altman
Co-Founder and Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Euan Ashley
Co-Founder and Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Michael Snyder
Co-Founder and Member of Clinical & Scientific Advisory Boardno datageen gegevensgeen gegevens
Kenneth Widder
Independent Director1.4yrsUS$154.00kgeen gegevens
Karin Eastham
Independent Chair of the Board5.2yrsUS$173.05k0.024%
$ 56.9k
Arthur Bowman
Independent Director5.5yrsUS$121.38k0.024%
$ 56.9k
Woodrow Myers
Independent Director3.7yrsUS$108.88k0.046%
$ 110.0k
John West
Advisor to the Board1.9yrsUS$5.62mgeen gegevens
Lonnie Shoff
Independent Director2.3yrsUS$103.88k0.018%
$ 43.4k
Olivia Bloom
Independent Director2.7yrsUS$116.38k0.031%
$ 74.1k

2.5yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PSNL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.